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Abstract
Background: Central nervous system (CNS) metastases develop in nearly half of patients with advanced melanoma and in 15–20% CNS 
is the first site of relapse. Median overall survival is short, ranging from two to four months, and one-year survival rate is only 10–15%. 
THA has been shown to have both anti-angiogenetic and immuno-modulating effects. TMZ is an oral alkylating agent with an excellent 
oral bioavailability and it is highly lipophillic with an ability to penetrate the blood–brain barrier. TMZ and THA in combination were tested 
in patients with brain metastases from malignant melanoma.
Methods: Between June 2004 and February 2007 patients with measurable metastatic melanoma in progression and PS ≤ 1 received 
TMZ in a dose of 150 mg/m2 qd for seven days, followed by seven days off therapy and THA in 200 mg qd, both orally administered. 
Concomitant treatment with steroids was allowed. PBMCs were collected from the last 14 consecutive patients for evaluation of immune 
parameters. 
Results: Forty screened patients were eligible and evaluable for response, and 39 were evaluable for toxicity. 25 patients had asymp-
tomatic and 15 symptomatic brain metastases. The toxicity was primarily grade 1–2 with no grade 4 or treatment-related deaths. Four 
patients had thromboembolic events grade 3. One patient obtained a CR and five a PR in the CNS, while two had CR and four had PR out-
side CNS. Overall response rate was 17.5%. We found a significant positive correlation between lymphopenia and objective response.
Conclusions: The combination treatment was well tolerated but with more frequent thromboembolic events compared to single drug 
TMZ or THA. The treatment demonstrated activity in CNS as well as outside CNS. The correlation between lymphopenia and objective 
response needs further investigation.
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Introduction
Malignant melanoma (MM) in the advanced stage has a poor prognosis. The disease is notorious for its propensity to metastasize and for 
its poor response to current medical therapeutic regimens, with median survival times in most studies ranging from six to nine months and 
five-year survival rate of less than 5% [1]. Furthermore, melanoma is the third most common cause of metastases in the central nervous 
system (CNS) after carcinomas of the lung and breast and develops in nearly 50% of patients with metastatic melanoma. CNS metas-
tases is the first failure site in approximately 40% among the 8–10% of patients with an initial complete response to high-dose IL-2-based 
therapy [2]. Median survival time in these patients is short, ranging from two to four months, and one-year survival rate is 10–15% [3].
Once patients develop brain metastases, treatment is palliative. Surgery and stereotactic radiotherapy can produce effective palliation in 
patients with a few CNS lesions [4]. In case of multiple or inoperable CNS metastases, whole brain radiotherapy is considered standard 
of care. Temozolomide (TMZ) is an oral, alkylating agent with a high oral bioavailability. It is highly lipophilic with an ability to penetrate the 
blood–brain barrier, and it has demonstrated activity in the treatment of brain metastases from MM [5]. The schedule for treatment with 
TMZ is of utmost importance. Compared to the standard dose of 150–200 mg/m2 five days every 28 days, extended dose permits a 2.1-
fold greater drug exposure over four weeks. Different schedules have been tried [6,7]. A lower dose per day but given continuously over 
a period of 6–8 weeks followed by a two-week rest has led to significant toxicity, with lymphopenia in up to 75% of the patients treated 
[8,9]. An increased depletion of the DNA repair enzyme 0(6)-alkylguanin-DNA alkyltransferase (AGAT) has been observed with the 
extended dosing, which may lead to enhanced anti-tumour activity. In patients treated with TMZ, the activity of the enzyme was measured 
in mononuclear cells in the blood [7]. Thalidomide (THA) was introduced in Europe and Canada in the late 1950s as a sedative and for 
the treatment of morning sickness in pregnant women. The drug was withdrawn from the market in the early 1960s because reports of 
teratogenecity associated with its use emerged [10]. D’Amato et al were the first to show the inhibitory activity of THA on angiogenesis 
in a rabbit model of corneal neovascularization induced by basic fibroblast growth factor (bFGF) and/or vascular endothelial growth fac-
tor (VEGF) [11]. Furthermore, THA inhibits the inflammatory response by decreasing cyclo-oxygenase-2 activity and by suppressing the 
synthesis of tumour necrosis factor-a (TNF-a) [12] by inducing TNF-a mRNA degradation [13]. THA enhances the production of IL-2 and 
IL-2 receptors, modulating the immune system to induce anti-cancer activity. The function of other cytokines, such as IL-6 and IL-12, are 
inhibited by THA, and it also modulates the expression of cell adhesion molecules [14–16]. THA has demonstrated clinical activity against 
a range of solid tumours, including melanoma [17]. We found in a phase-II trial that THA as single agent has some extra-cranial activity in 
patients with brain metastases from MM but no objective response was seen in the brain [18]. Hwu et al reasoned that additional benefit 
might be gained by combining TMZ with THA and that the combination of continuous daily oral TMZ and THA appears to be a promising 
oral regimen for the treatment of MM, particularly in patients with brain metastases [19]. With the intention of optimizing this regimen we 
have conducted a phase-II trial with TMZ using extended dose, 150 mg/m2 qd for seven days, followed by seven days off therapy and 
THA 200 mg qd.
Materials and methods
Patients
All patients included in the study had brain metastases in progression not amenable for surgery or stereotactic radiotherapy and due 
to limited symptoms whole brain radiotherapy was not indicated. WHO performance status (PS) ≤ 0.1. Further inclusion criteria were: 
measurable disease in the brain, defined as ≥ 1.0 cm in diameter on spiral CT or MRI. Concomitant steroids were allowed for patients 
with clinical evidence of brain metastases. Lesions within a previous radiation field had to have shown recent disease progression to be 
considered evaluable. Previous treatment with IL-2, other biologic therapy or radiotherapy must have been completed ≥ 4 weeks prior to 
study enrolment. Eligible patients also met the following criteria: WBC ≥ 3.0 x 109/l, ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, serum alanine 
aminotransferase and alkaline phosphatase levels < 2.5 UNL and bilirubin and creatinine ≤ 1.5 UNL. All patients were obliged to comply 
with Pharmion’s Risk Management Programme, conducted according to the System for Thalidomide Education and Prescribing Safety 
(STEPS) guidelines [20]. Female patients were required to have negative urine pregnancy test, within 24 hours prior to THA therapy. Any 
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women of child-bearing potential had to use adequate contraceptive methods during the study and for 28 days after the last THA dose. 
Men were required to use condoms in connection with any sexual activity. Pregnant or nursing women were excluded. All patients pro-
vided written informed consent.
Treatment and patient evaluation
Starting dose of THA was 100 mg qd orally, taken in the evening to reduce drug-related daytime somnolence. The dose was escalated after 
one week to a maximum of 200 mg qd given continuously. Concomitantly, patients received treatment with TMZ 150 mg/m2 qd for seven 
days, followed by seven days off therapy. Treatment was continued until unacceptable toxicity, patient refusal or disease progression.
Toxicity was assessed according to Common Toxicity Criteria (CTC v3.0) [21]. The dose of THA was interrupted in cases of myelotoxicity, 
constipation or somnolence grade 3–4 and could be resumed if toxicity was reduced to grade 1. In cases of treatment interruption due to 
THA related myelotoxicity or constipation, somnolence (≥ grade 2) or neuropathy (> grade 2), treatment could be restarted with 50% dose 
reduction. No dose re-escalation was performed. In cases of grade 4, neuropathy treatment was stopped.
Dose modification guidelines for TMZ allowed for interruption of treatment in the event of any grade 3–4 toxicity, until toxicity resolved to 
≤ grade 1 or baseline level. Subsequently, TMZ would be restarted at a dose of 112.5 mg/m2/d. With subsequent toxicity > grade 2 doses 
would be reduced to 75 mg/m2/d, which was the lowest allowed dose. Re-escalation of the dose was not allowed.
One treatment cycle was defined as a four-week period. Clinical evaluation was performed after the initial two and four weeks in order to 
perform proper dose correction. Thereafter, patient clinical evaluation was performed at four-week intervals to assess toxicity and clinical 
benefit. During each visit, a complete blood count was taken, combined with evaluation of blood pressure, weight and performance status.
Response to treatment was assessed after three cycles according to RECIST [22], by physical examination and CT or MRI of all meta-
static sites. In case of disease progression prior to first evaluation, treatment was stopped and the patient was designated as having 
progressive disease (PD). In case of stable disease (SD) or an objective response, partial response (PR) or complete response (CR), 
treatment was continued.
Identification of lymphopenia
The absolute lymphocyte count (ALC) was determined together with the complete blood count during each visit. Lymphopenia was defined 
as ALC < 0,8 x 109/l corresponding to CTC grade 2. Severe lymphopenia was considered to be ALC < 0.5 x 109/l (≥ grade 3 lymphopenia). 
Initially, prophylactic antibiotics were not administered for lymphopenia, but following cases of opportunistic infections occurring among 
the first 15 patients enrolled in the study. We started to administer prophylactic antibiotics (Sulfamethoxazol/Trimetoprim two tablets three 
times a week) to patients with grade 2 lymphopenia and fever > 38º and to patients with ≥ grade 3 lymphopenia with or without fever.
Analysis of T-cell populations
Three peripheral blood samples were obtained from the last 12 patients enrolled in the study. One before treatment with THA and TMZ 
(pre-sample), one after treatment day 14 and one on day 28. Mononuclear cells (MNC) were purified using leucosep® tubes (Greiner 
Bio-One GmbH, Germany). Red blood cells were lysed and MNCs were cryopreserved in foetal bovine serum (FBS) (Gibco, Invitrogen, 
Carlsbad, CA, USA) containing 5% DMSO until use. For staining of CD4+CD25+FOXP3+ Treg cells the PE anti-human FOXP3 staining kit 
from eBioscience was used (eBioscience, San Diego, CA, USA). In brief, cells were stained with FITC anti-human CD127, PE anti-human 
FOXP3, PerCP anti-human CD4, APC anti-human CD25 and the relevant isotype controls as recommended by the manufacturer. The 
cells analysed on a FACSdiva (Becton Dickinson). The collection was stopped after acquiring 200,000 events, and data were analysed 
using FACSdiva software (Becton Dickinson). For defining the population of Treg cells, the cells were first gated on CD4
+ lymphocytes 
then on CD4+ and CD25high. On the pre-sample, the level of CD4+CD25high out of CD4+ T cells was fixed at 2%, and the following two 
samples (day 14 and day 28) were analysed on the same day using the same gates. To confirm that the cells within the gate were Treg 
cells, we evaluated the FOXP3 expression and found the FOXP3 expression to be between 80–95%. When evaluating the level of 
CD4+CD127+CD25neg-int T cells, the cells were gated on CD4+ lymphocytes then on CD127+ and CD25neg-int.
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Statistical analysis
This single-institution phase-II study was approved by the Ethics Committee of Funen County. The primary objective of the study was 
to determine response rate of the study treatment according to RECIST, whereas estimation of time to progression, overall survival and 
evaluation of tolerability of the regimen were secondary objectives. Patients were accrued to this study using a two-stage Simon’s design 
[23] in order to improve the probability of observing the true response rate. Thus, if there were three or more responders among the first 
21 evaluable patients, the accrual would be extended to a total of 40 evaluable patients with five patients per responder with an esti-
mated response rate of 25%. Descriptive statistics were used to describe baseline patient characteristics, the cerebral and extra-cerebral 
objective response rate and toxicity. Time to progression and death were estimated using the Kaplan-Meier method, with overall survival 
measured from study entry until death from any cause. The T-cell data were analysed using a student t test.
Results
Patient characteristics
A total of 43 patients were enrolled in the study between June 2005 and February 2007. Three patients did not meet protocol eligibil-
ity requirements and were excluded from all analyses. Baseline patient and disease characteristics for 40 eligible patients (21 men, 19 
women) are shown in Table 1. Thirty-nine patients were evaluable for toxicity as one patient died shortly after the start of treatment. 
Median age of the patients was 55 years (range: 29–76 years), 16 patients were in WHO PS: 0 and 24 in PS: 1. All patients had non-
resectable brain metastases in progression: 15 had minor neurologic symptoms and were treated with concomitant steroids. The remain-
ing 25 patients had asymptomatic brain metastases all found during screening procedures prior to planned IL-2-based therapy. Among 
40 patients, 34 had known primary cutaneous melanoma, six had unknown primary melanoma. Thirty-nine patients had concomitant 
extensive extra-cranial disease with 15% having liver metastases and 57% having lung metastases. Before study entry, four patients had 
received whole-brain radiotherapy, one had received stereotactic radiotherapy and three had undergone surgery for brain metastases. 
Seven patients had received prior immunotherapy and none prior cytotoxic therapy. The patients completed a median of three cycles of 
therapy (range: 1–10 cycles). Eight patients received only one cycle because of early clinical disease progression. Twenty-seven patients 
completed three cycles and were evaluated for efficacy.
Analysis of lymphopenia
All 40 patients were analysed for lymphopenia. Eight patients experienced no lymphopenia during treatment; five patients experienced 
grade 1; eight patients grade 2; 16 patients grade 3; and eventually three patients experienced grade 4 lymphopenia (< 0.2 x 109/l ). The 
observed lymphopenia rate was 68%.
Analysis of T-cell populations
A total of 12 patients were analysed for the presence of CD4+CD25+FOXP3+ Treg cells. None of the patients included in the analysis had 
objective response during treatment with THA and TMZ (eight patients had PD and four patients had SD). The percentage of Treg cells out 
of CD4 T cells was increased after treatment with TMZ and THA (p=0.001) (Figure 1A), while the total number of Treg cells was unchanged 
after treatment (p=0.8) (Figure 1B). The percentage of CD4 T cells out of lymphocytes (p=0.03) as well as the total number of CD4 T cells 
(p=0.04) decreased during treatment (Figure 2A and B). Furthermore, a decreased percentage of CD4+CD127+CD25neg-int T cells out of 
CD4 T cells (p=0.0001) along with a tendency to a decreased number of total CD4+CD127+CD25neg-int T-cells were observed (Figure 3). 
However, the latter did not reach statistical significance (p=0.2).
Toxicity
The reported non-haematologic adverse events are summarized in Table 2. The toxicity was primarily grade 1–2 with fatique, constipation 
and mouth dryness. Four had thromboembolic events (TEE) all grade 3, which did not result in discontinuation of therapy. These patients 
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were treated with anti-coagulants. Except for one patient with pancytopenia grade 3, no significant neutropenia or thrombocytopenia and no 
grade 4 or treatment-related deaths was observed. Thirteen patients were treated with antibiotics because of lymphopenia. Among these, 
three patients had opportunistic infections or other infections indicative of T-cell dysfunction with one patient having systemic infection with 
Candida Albicans in the lungs and two patients with Legionella. During the study, only two patients discontinued study treatment because 
of toxicity. One patient discontinued because of grade 3 nausea and vomiting, possibly related to the study drug and one patient because of 
grade 3 haematologic toxicity. Disease progression was the most common reason for treatment discontinuation (62% of cases).
Response
Objective response rates according to RECIST in the brain and outside CNS are shown in Table 3. Among the 40 patients, one patient 
obtained a CR in the brain, five a PR and ten a SD. Outside CNS, two patients obtained a CR, four a PR and ten a SD. One patient 
obtained a CR overall, while six patients had PR, leading to an overall response rate of 17.5%. Unfortunately, planned confirmation of 
response according to RECIST was not a part of our protocol; therefore, only four out of seven responses were confirmed after three 
months. A further eight patients had SD in both CNS and outside CNS, leading to a clinical benefit rate of 37.5%. The three patients 
referred to as non-evaluable for response outside the CNS were all patients with metastases in the brain as the only metastatic site. 
Among the seven patients who had an overall objective response, three were treated with concomitant steroids, four had symptomatic 
and three had asymptomatic brain metastases.
Table 1: Patient characteristics (n = 40)
ecancer 2008, 2:91
www.ecancermedicalscience.com6
Re
se
ar
ch
 A
rti
cl
e
The correlation between lymphocyte count and response to treatment is shown in Table 4. Patients with SD have been categorized 
together with patients obtaining an objective response. We find a statistically significant correlation between efficacy and lymphopenia 
(Fishers exact test, p= 0.01). The Kaplan-Meier estimate of time to progression is shown in Figure 4. Median time to progression was 2.7 
months (95% conf lim: 0.3–9.3 months). Kaplan-Meier estimate of overall survival is shown in Figure 5. The median survival time was 4.2 
months (95% conf lim: 0.8–14.0 months). No difference in survival comparing patients with symptomatic (n=15) and asymptomatic (n=25) 
brain metastases was found (data not shown).
Discussion
In this phase II trial, we have investigated the combination of THA and a dose-intensified schedule of TMZ 150 mg/m2 seven days on/
seven days off, in the treatment of malignant melanoma with brain metastases. In our study, we observed a response rate of 17.5% and 
a clinical benefit rate (CR + PR + SD) of 37.5%. The response rate using the classical schedule of TMZ single drug leads to a response 
Table 2: Toxicity profile in 39 evaluable patients
Table 3: Response in 40 patients
Table 4: Significant correlation between response and 
lymphocyte count p2=0.01
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rate of 6–9% [24,25], with further 10% obtaining SD. These two studies were the first to demonstrate any anti-tumour activity of TMZ in 
brain metastases of melanoma patients. A phase-II study by Schadendorf et al [26] using dose-intensified bi-weekly TMZ did not lead to 
significant response in brain metastases or extra-cerebral metastatic lesions (under 5%) [26]. A small study with extended dose of TMZ 
(six weeks, low dose) combined with THA showed a response rate of 12% and a clinical benefit of up to 31% in 26 patients [19,27]. Our 
study is the first phase-II study published combining the cyclic (seven days on/seven days off) regimen of TMZ and THA for patients with 
malignant melanoma suffering from brain metastases, showing a meaningful response rate.
Su et al were the first to report lymphopenia and opportunistic infections as an unexpected toxicity of extended-dose regimens of TMZ in 
melanoma patients [8]. They reported their retrospective experience with patients receiving this regimen alone or combined with either 
THA or low-dose interferon-alpha. Lymphopenia was not more common in patients treated with TMZ combined with THA, compared to 
TMZ alone. CD4+ lymphopenia was seen in 60% of patients, leading to opportunistic infections as well as other infections indicative of 
T-cell dysfunction. They concluded that Pneumocystis pneumonia prophylaxis should be considered for patients who develop sustained 
lymphopenia on TMZ. We can conclude the same from our study. We observed grade 2–4 lymphopenia during treatment in 27 of the 40 
patients (67%). Interestingly, in this subgroup of patients significantly more responders were seen, indicating that immune parameters 
might influence the response of this combination regimen. From the study of Su et al [8], analysis by flow cytometry showed that the abso-
lute CD4+ T-cell counts were depressed and that the CD4+CD25+ T-cell subset in some patients was markedly depressed, indicating that 
the lymphopenic effect of TMZ is relatively specific for the CD4+ subset.
Lately, it has become clear that Treg cells might play a role in inhibiting beneficial anti-tumour immune responses [28]. Treatment of can-
cer patients with low doses of cyclophosphamide has resulted in the depletion of Treg cells, which in theory might improve anti-tumour 
immunity [28,29]. Thus, we evaluated the impact of TMZ and THA on the Treg cell populations to determine whether the treatment had any 
effect on these cells. When analysing the presence of CD4+CD25+FOXP3+ Tregs in patients treated with TMZ and THA, we found that the 
Figure 4: Kaplan-Meier estimate of time to progression in 40 patients. Median time to progression is 2.7 months (95% conf lim: 0.3–9.3 mths)
ecancer 2008, 2:91
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percentage of Treg cells out of CD4 T cells was increased after treatment. However, this increase in Treg cell proportion did not result in 
an increased total number of Treg cells, since the percentage of CD4 T cells after treatment was lowered. Others have observed a prefer-
ential lymphopenia in the CD4+ compartment in melanoma patients after treatment with TMZ8. In the present study, we also observed a 
lowered percentage of CD4+ T cells out of total lymphocytes along with a lowered total number of CD4+ T cells after treatment with TMZ 
and THA. This indicates that other subsets of CD4+ T cells apart from the Treg cell subset are sensitive to the treatment. Interestingly, 
when evaluating the fraction of CD4+CD127+CD25neg-int out of CD4+ T cells, we found that this was lowered. Furthermore, we observed a 
tendency towards a lower number of total CD4+CD127+CD25neg-int T cells after treatment, suggesting that these cells were influenced by 
TMZ. The expression of CD127 is down regulated on activated effector CD4 T cells [30], as well as on Treg cells [31,32], thus it seems that 
TMZ affects the CD127+CD25neg-int subset, which mostly contains conventional naïve T cells [33] and memory T cells [34]. Unfortunately, 
we only obtained data from patients with PD and SD. Thus, we are unable to report whether the CD4 T cell subsets fluctuate in a similar 
way in patients responding to the treatment with TMZ and THA or if they change at all. This will be evaluated in an ongoing trial.
The TMZ and THA treatment was well tolerated with mainly grade 1–2 non-haematological toxicity and no significant haematological tox-
icity. However, the combination had significantly more TEE than either Thalidomide or TMZ alone [18,35]. It has previously been shown in 
multiple myeloma that, when THA is combined with cytotoxic agents or with steroids, the frequency of TEE increases [36]. Furthermore, 
it is well known that cancer in itself is associated with a higher risk of TEE [37]. This was the case in the study performed by CALGB [24], 
which was suspended and subsequently closed because of severe TEE and limited number of objective responses. In the CALGB study, 
THA was given in doses up to 400 mg daily. The lower dose of THA in our study may explain the more manageable TEEs in four patients 
having deep-vein thrombosis and none of the patients developing pulmonary embolism. No significance can be established because of 
the small number of patients; however, in future studies one should be aware of this complication associated with this treatment combina-
tion and should maybe use lower doses of THA.
We conclude that the combination of TMZ, using the bi-weekly dose-intense schedule and THA 100–200 mg/d, is a safe regimen, leading to 
clinical efficacy in patients with brain metastases from malignant melanoma. Most importantly, it seems that patients who develop lymphopenia 
Figure 5: Kaplan-Meier estimate of overall survival in 40 patients. Median survival time is 4.2 months (95% conf lim: 0.8–14.0 months)
www.ecancermedicalscience.com9
ecancer 2008, 2:91
Re
se
ar
ch
 A
rti
cl
e
during therapy have a higher chance of obtaining objective response. The potential immunologic mechanism behind this will be the subject of 
future investigations, focusing on the potential benefit of Treg down regulation. Further evaluations using larger patient numbers and including 
different therapy schedules will be considered for the future. Concerning the schedule of TMZ, we await the ongoing EORTC 18032 phase-III 
trial, investigating the bi-weekly regimen of TMZ versus standard Dacarbazine in previously untreated patients with metastatic melanoma.
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Supplementary figures
Figure 1: Percentage and total number of Treg cells in malignant melanoma patients before and after treatment with thalidomide and temo-
zolomide. MNCs were stained with PE anti-human FOXP3, PerCP anti-human CD4, APC anti-human CD25. For defining the population of Treg 
cells, the cells were first gated on CD4+ lymphocytes then on CD4+ and CD25high. On the pre-sample, the level of CD4+CD25high out of CD4+ 
T cells was fixed at 2% and the following two samples (day 14 and day 28) were analysed on the same day using the same gates. To confirm 
that the cells within the gate were Treg cells, we evaluated the FOXP3 expression and found the FOXP3 expression to be between 80%-95%. 
(A) Percentage of Treg cells out of CD4 T cells. (B) Total number of Treg cells/µl blood 
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Figure 2: Percentage and total number of CD4 T cells in malignant melanoma patients before and after treatment with thalidomide and temo-
zolomide. (A) Percentage of CD4 T cells out of lymphocytes. (B) Total number of CD4 T cells
www.ecancermedicalscience.com13
ecancer 2008, 2:91
Re
se
ar
ch
 A
rti
cl
e
Figure 3: Percentage and total number of CD4+CD25neg-intCD127+ T cells in malignant melanoma patients before and after treatment with 
thalidomide and temozolomide. MNCs were stained with FITC anti-human CD127, PerCP anti-human CD4, APC anti-human CD25. When evalu-
ating the level of CD4+CD127+CD25neg-int T cells, the cells were gated on CD4+ lymphocytes then on CD127+ and CD25neg-int 
